Efficacy of Live-Attenuated H9N2 Influenza Vaccine Candidates Containing NS1 Truncations against H9N2 Avian Influenza Viruses

Sujuan Chen1,2,3†, Yinbiao Zhu1,2,3,4†, Da Yang1,2,3, Yang Yang1,2,3, Shaohua Shi1,2,3, Tao Qin1,2,3, Daxin Peng1,2,3* and Xiufan Liu1,2,3

1 College of Veterinary Medicine, Yangzhou University, Yangzhou, China, 2 Jiangsu Research Center of Engineering and Technology for Prevention and Control of Poultry Disease, Yangzhou, China, 3 Jiangsu Co-innovation Center for the Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou, China, 4 Yangzhou Vac Biological Engineering Co., Ltd., Yangzhou, China

H9N2 avian influenza virus is a zoonotic agent with a broad host range that can contribute genetic information to H5 or H7N9 subtype viruses, which are significant threats to both humans and birds. Thus, there is a great need for a vaccine to control H9N2 avian influenza. Three mutant viruses of an H9N2 virus A/chicken/Taixing/10/2010 (rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128) were constructed with different NS1 gene truncations and confirmed by western blot analysis. The genetic stability, pathogenicity, transmissibility, and host immune responses toward these mutants were evaluated. The mutant virus rTX-NS1-128 exhibited the most attenuated phenotype and lost transmissibility. The expression levels of interleukin 12 in the nasal and tracheal tissues from chickens immunized with rTX-NS1-128 were significantly upregulated on day 3 post-immunization and the IgA and IgG antibody levels were significantly increased on days 7, 14, and 21 post-immunization when compared to chickens that received an inactivated vaccine. rTX-NS1-128 also protected chickens from challenge by homologous and heterologous H9N2 avian influenza viruses. The results indicate that rTX-NS1-128 can be used as a potential live-attenuated vaccine against H9N2 avian influenza.

Keywords: H9N2, avian influenza virus, attenuation, NS1, vaccine

INTRODUCTION

H9N2 avian influenza viruses (AIVs) are endemic to Chinese poultry farms and cause economic losses to the breeding industry. H9N2 AIVs can also cross species barriers to cause non-lethal human infections (Peiris et al., 1999; Butt et al., 2005). Moreover, H9N2 AIVs can contribute their internal genes to new emerging reassortant viruses such as H7N9 (Wu et al., 2013) and H10N8 (Chen et al., 2014), which are great threats to public health. Thus, effective prevention and control of H9N2 avian influenza is crucial.

Vaccination is the most effective method of prophylaxis against influenza. Currently in Mainland China, only inactivated vaccines are licensed for use to control H9N2 subtype AIVs.
However, recently there were reports that H9N2 subtype avian influenza still causes outbreaks on chicken farms for which H9N2 AIV immunization had been implemented (Liu et al., 2003; Li et al., 2005). The failure of vaccination based on inactivated vaccine can be due in part to the antigenic drift of H9N2 (Sun et al., 2010).

Unlike inactivated vaccines that only induce humoral immune responses, live-attenuated vaccines (LAVs) can stimulate humoral, cellular and mucosal immune responses, which provide greater cross-protection and longer-lasting immunity (Suguitan et al., 2006; Joseph et al., 2008). Furthermore, LAVs can also be administered using aerosols or liquids (Allan et al., 1978). Cold-adapted live-attenuated influenza viruses generated through consistent low-temperature cultivation have exhibited good efficacy and safety in human populations (Fleming et al., 2006). Besides cold-adapted LAVs, some influenza mutant viruses of subtypes H1 (Zhou et al., 2010), H5 (Talon et al., 2000), and H7 (Wang et al., 2008) expressing truncated NS1 genes display highly attenuated phenotypes both in vivo and in vitro, with potential to become live-attenuated vaccine candidate strains.

Given that H9N2 subtype AIVs contribute gene segments to novel reassortant viruses such as H7N9 (Wu et al., 2013) and H10N8 (Chen et al., 2014), as well as their own potential threat to public health, it is crucial to develop an effective live-attenuated vaccine to control H9N2 avian influenza. Wei et al. (2016) show that a cold-adapted live-attenuated H9N2 subtype AIV vaccine can provide protection of chickens from homologous and heterogenous H9N2 viruses. However, construction of H9N2 subtype AIV with truncated NS1 gene as a live vaccine for poultry has not been reported. Here we constructed three NS mutant viruses (rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128) of H9N2 subtype AIV by using reverse genetics. These mutant viruses were attenuated to different degrees in chickens. The virus rTX-NS1-128 was most attenuated, induced humoral, cellular, and mucosal immune response, and protected chickens from challenge by homologous and heterologous wild-type H9N2 viruses.

MATERIALS AND METHODS

Biosafety and Animal Care
All experiments were conducted in BSL-2 under the guidelines of Jiangsu Laboratory Animal Welfare and Ethical of Jiangsu Administrative Committee of Laboratory Animals (Permit number SYXKSU-2007-0005).

Viruses and Cells
H9N2 AIVs A/chicken/Shanghai/F/98 (F98) and A/chicken/ Taixing/10/2010 (TX) (Zhu et al., 2015a,b) were propagated in 10-day-old specific-pathogen-free (SPF) embryonated chicken eggs. The allantoic fluids containing virus were harvested and stored at −70°C. Human embryonic kidney cells (293T) and Madin-Darby canine kidney (MDCK) cells were cultured in Dulbecco’s modified Eagles’ medium (DMEM) with 10% (v/v) fetal bovine serum (HyClone, Logan, UT, United States) at 37°C and 5% CO2.

Generation and Propagation of Mutant Viruses
Wild-type (WT) H9N2 AIV TX was created by plasmid-based reverse genetic technology (Hoffmann et al., 2000). The cDNAs of the eight gene segments of TX were cloned into plasmid pHW2000, confirmed by DNA sequencing, and named as pHW291-PB2, pHW292-PB1, pHW293-PA, pHW294-HA, pHW295-NP, pHW296-NA, pHW297-M, pHW298-NS. Deletions were introduced into the plasmid pHW298-NS using overlap-PCR to generate the three mutant NS segments (Figure 1A): pHW298-NS 1-73, pHW298-NS 1-100, and pHW298-NS 1-128. Nucleotides 220–456 (NS1 GenBank Accession Number: JN653684) were replaced by stop codons to generate pHW298-rTX-NS1-73; nucleotides 301–456 were replaced by stop codons to generate pHW298-NS 1-100; nucleotides 385–456 were replaced by stop codons to generate pHW298-NS 1-128. The recombinant viruses rTX, rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128 were generated by co-transfection of eight reverse-genetic plasmids with or without the substitution plasmids pHW298-NS into co-cultured 293T/MDCK cells. Plasmids (300 ng) encoding each gene segment were mixed and incubated with 15 μl of Lipofectamine 2000 (Invitrogen) at room temperature for 15 min. The Lipofectamine-DNA mixture was transferred to 80% confluent 293T/MDCK cells co-cultured in 35 mm dishes and incubated at 37°C with 5% CO2 for 8 h. Transfection supernatants were replaced with 2 ml of Opti-MEM 1 medium (Invitrogen) plus 0.3% BSA fraction V (Invitrogen) and 2 μg/ml TPCK-trypsin (Worthington, Lakewood, NJ, United States). Three days post-transfection, the supernatants were collected and subsequently inoculated into 7-day-old embryonated chicken eggs with incomplete Interferon (IFN)-system response for virus propagation (P1 stock). Viral stocks were then inoculated into 10-day-old SPF embryonated chicken eggs to obtain viral stocks. Viral stocks were aliquoted and subsequently stored at −70°C for additional experiments. Viral titers were determined by 50% tissue culture infectious dose (TCID50) in MDCK cells. Sequencing was performed to confirm the identity of the NS gene.

Western Blot Analysis
Confluent MDCK cells were infected with the mutant viruses and WT virus at a multiplicity of infection (MOI) of 1 for 1 h at 37°C in 5% CO2. The infected cells were washed three times with PBS and then fresh opti-MEM (Thermo Fisher Scientific) with 2 μg/ml TPCK trypsin was added. Viral proteins extracted from cells at 3 h post-infection were electrophoresed on a 15% Tris-glycine gel and transferred onto a PVDF membrane. The membrane was blocked in 5% fat-free milk and incubated with polyclonal antibody (anti-NS1 of H9N2 AIV mouse serum), followed by incubation with horseradish peroxidase (HRP)-conjugated goat anti-mouse antibodies (EMD Chemicals Inc., San Diego, CA, United States). Protein bands were visualized using enhanced chemiluminescence (Thermo Fisher Scientific Inc., Rockford, IL, United States) on a chemiluminescence imaging analysis system.
Replication Kinetics in Cell Cultures and SPF Embryonated Eggs
Confluent monolayers of MDCK cells were infected with rTX or NS mutant viruses at a MOI of 0.001 in triplicate. One-hour post-infection (hpi), the inoculum was removed, and cells were washed twice and added with DMEM supplemented with 0.15% BSA fraction V and 2 µg/ml TPCK-trypsin. Supernatants were collected at 12, 24, 48, and 72 hpi and titrated in MDCK cells. Ten-day-old SPF embryonated chicken eggs were infected with each virus (diluted 10-fold in PBS). After 72 h of incubation at 37°C, allantoic fluids were harvested and used in HA assays to calculate the EID$_{50}$ according to the method of Reed and Muench (1938).

Pathogenicity in Chickens
The virulence of the viruses was determined in 4-week-old SPF chickens. Eleven chickens were intranasally infected with 10$^6$ EID$_{50}$/0.2 ml of rTX or each NS mutant virus and three infected chickens were sacrificed on 3 and 5 days post-inoculation (dpi) to collect trachea and lung tissues for virus titration. In addition, viral shedding was also determined by titrating oropharyngeal and cloacal swabs collected and suspended in 1 ml PBS on both 3 and 5 dpi. All tissue and swab samples were titrated for viral infectivity by EID$_{50}$.

Dose-Response and Transmissibility Study in Chickens
Ten groups of five 4-week-old SPF chickens were intranasally inoculated with 10$^5$–10$^7$ EID$_{50}$/0.2 ml of rTX or rTX-NS1-128. Five additional chickens were added to each group at 24 h post-challenge for contact transmission studies. Oropharyngeal and cloacal swabs were collected on both 3 and 5 dpi for viral shedding determinations. Blood was collected to isolate serum on 21 dpi for seroconversion assays.

Cytokine mRNA Expression and IgA and IgG Secretion in Mucosa
Groups of twenty five 4-week-old SPF chickens were inoculated intranasally with 10$^6$ EID$_{50}$ of rTX-NS1-128 or PBS in 0.2 ml, or inoculated subcutaneously with 0.2 ml oil-emulsion inactivated vaccine of 10$^6$ EID$_{50}$ rTX. Chickens were euthanized on days 1, 3, 7, 14, and 21 post-immunization. Tracheal and nasal samples of inoculated chickens on days 1 and 3 post-immunization were collected for RNA extraction. The relative expression levels of IL-2, IL-6, and IL-12 were determined using real-time RT-PCR with the following primers: IL-2 (Forward: 5′-GAACCTCAAGAGTCTTACGGGTCTA-3′; Reverse: 5′-ACAAATTGGTCAGTTCTATGGAGA-3′), IL-6 (Forward: 5′-CGGCAGATGGTGATAAATCC-3′; Reverse: 5′-CCCTCAGGGTC TCTCCATA-3′), IL-12 (Forward: 5′-ACCAGCCGACTTAGATGTTCC-3′; Reverse: 5′-GGTCTCCAGGGTCCTTGGATA-3′), and internal reference gene β-actin (Forward: 5′-ATGAAACCCAGAGCAAAAAGA-3′; Reverse: 5′-GGGGTGTTGAAGGTCTCACA-3′). Lavage liquids from nasal cavity and trachea of inoculated chickens were collected at 7, 14, and 21 days post-immunization by repeated washing with 0.5 ml of PBS. The lavage liquids were centrifuged at 3,000 x g at 4°C for 15 min. The supernatant was collected for detection of AIV specific
Comparisons of experimental groups were estimated using statistical analysis evaluated at days 3 and 5 post-challenge.

and mortality after challenge, and viral shedding in the swabs was with 10 weeks after inoculation, chickens were challenged intranasally with 10 µg/ml rTX (10 EID₅₀/mL diluted in PBS; Bethyl Laboratories, Inc.) was used as second antibody, followed by HRP-linked rabbit anti-goat IgG (1:20000 diluted in PBS; Medical & Biological Laboratories Co., Ltd.). The absorbance was read at 450 nm using a microplate reader.

**Vaccination and Challenge in Chickens**

Four-week-old SPF chickens were inoculated intranasally with 10⁶ EID₅₀ virus or PBS in 0.2 ml (n = 10 per group). Three weeks after inoculation, chickens were challenged intranasally with 10⁵ EID₅₀ of H9 subtype viruses (TX or F98) to determine protective efficacy. Chickens were monitored daily for morbidity and mortality after challenge, and viral shedding in the swabs was evaluated at days 3 and 5 post-challenge.

**Statistical Analysis**

Comparisons of experimental groups were estimated using t-tests with two-tailed analysis to determine significant differences. p-values < 0.05 were considered statistically significant.

**RESULTS**

**Mutant Virus Rescue and Western Blotting Analyses**

Three different NS1 gene truncations encoding either 73, 100, or 128 amino acids were constructed in the backbone of H9N2 influenza virus (TX) using reverse genetics. The rescued recombinant viruses were confirmed by RT-PCR amplification (Figure 1B) and sequence analysis of NS gene (Supplementary Figure S1). The three NS1 mutants were purified using limited-dilution method through 10-day-old embryonated chicken eggs. After purification, the variants were passaged at least five times in 10-day-old embryonated chicken eggs. No additional mutations other than the engineered NS1 truncations were observed.

To analyze expression of truncated viral NS1 protein, western blot was performed to examine the mobility change of the NS1 protein. The NS1 proteins from rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128 viruses showed a reduced molecular weight as expected, when compared to the rTX virus (Figure 1C), indicating successful construction of the mutant viruses.

**Characterization of Mutant Viruses**

The growth properties of the NS1 mutant viruses and wild type virus rTX were compared in MDCK cells and 10-day-old SPF embryonated chicken eggs. All viruses replicated well in SPF embryonated chicken eggs with their titers ranging between 7.47 and 8.08 EID₅₀/0.1 ml. Although the titer of each mutant virus was lower than that of wild type virus at 48 and 72 hpi. Neither the wild type rTX nor the mutant viruses replicated in Vero cells.

**Attenuation of Mutant Viruses in SPF Chickens**

To examine the level of attenuation of the NS1 mutant viruses, chickens were inoculated intranasally with 10⁶ EID₅₀ of the wild-type and mutant viruses. No experimentally infected chicken had clinical signs of disease after 14 dpi.

In trachea tissues on 3 dpi, the titer of rTX (5.0 ± 0.43 EID₅₀/g) was higher than that of rTX-NS1-73 (3.75 ± 0.66 EID₅₀/g), rTX-NS1-100 (3.66 ± 0.80 EID₅₀/g), and rTX-NS1-128 (3.16 ± 0.64 EID₅₀/g), with significant difference between rTX and rTX-NS1-128 (p < 0.05). On 5 dpi, only rTX and rTX-NS1-73 were able to replicate in trachea tissues, at titers of 2.83 ± 0.29 and 1.74 ± 0.20 EID₅₀/g, respectively (Figure 3A). In lung tissues, only wild type rTX was able to replicate on 3 dpi. The mutant viruses did not replicate in lungs at 3 dpi. No viruses were detected in 5 dpi samples (Figure 3B).

Viral shedding level of mutant viruses and wild type virus were assayed through titrating oropharyngeal and cloacal swabs (Table 2). On 3 dpi, rTX, rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128 viruses were all shed from oropharynx samples are viral shedding rates of 100, 90, 90, and 80%, respectively. On 5 dpi, rTX was still shed from all samples while the shedding

**TABLE 1** EID₅₀ of WT and NS-truncated viruses.

| Virus       | Log₁₀EID₅₀/0.1 ml |
|-------------|------------------|
| rTX         | 8.08             |
| rTX-NS1-73  | 7.47             |
| rTX-NS1-100 | 7.66             |
| rTX-NS1-128 | 7.65             |

**FIGURE 2** Virus replication in MDCK cells. Cells were infected at a multiplicity of infection of 0.001. Viruses at indicated times post-inoculation were titrated in MDCK cells and expressed as log₁₀ TCID₅₀/mL. The mean and standard errors are shown from three independent experiments. Asterisks represent p-values < 0.05.
rates of rTX-NS1-73 and rTX-NS1-100, and rTX-NS1-128 were reduced to 80, 70, and 50%, respectively. On 7 dpi, only rTX was detected in oropharyngeal swabs. No NS1 mutant virus was detected in cloacal swabs, while rTX was detectable in cloacal swabs on both 3 and 5 dpi. The titer of rTX in oropharyngeal swabs (6.05 ± 0.55 EID<sub>50</sub>/0.1 ml) was significantly higher than the titers of each NS1 mutant virus on 3 dpi (Table 2). HI antibody titers induced by NS1 mutant viruses were similar to that induced by rTX at 21 dpi (Table 2).

Dose-Response and Transmission Study of rTX-NS1-128 in Chickens

Since rTX-NS1-128 was the most attenuated virus but had similar immunogenicity as compared to the other viruses, it was used in subsequent dose-response and transmission studies to evaluate its potential as a live vaccine. Several groups of chickens were inoculated intranasally with rTX and NS1 mutant viruses at doses ranging from 10<sup>2</sup> to 10<sup>4</sup> EID<sub>50</sub>. One day after inoculation, five chickens were housed with virus-inoculated chickens as contact groups. Virus rTX was shed from all oropharynx and cloacal samples from chickens inoculated at 10<sup>3</sup>–10<sup>5</sup> EID<sub>50</sub>. rTX was also transmitted to contact group chickens. Viral shedding rates decreased to ~60% when chickens were inoculated with 10<sup>3</sup> EID<sub>50</sub> rTX. Inoculating chickens with 10<sup>3</sup> EID<sub>50</sub> rTX did not yield virus from oropharynx and cloacal samples from either inoculated or contact groups, but did lead to seroconversion in all chickens on 21 dpi (Table 3). In contrast to virus rTX, rTX-NS1-128 was only shed from chickens inoculated with 10<sup>6</sup> to 10<sup>7</sup> EID<sub>50</sub>. However, rTX-NS1-128 was not transmitted to contact chickens and did not lead to seroconversion (Table 3).

Cytokine mRNA Expression and IgA and IgG Secretion in Mucosa

To evaluate aspects of cellular and mucosal immunity, cytokine expression and secretion of IgA and IgG in nasal tracheal tissues were determined. IL-12 expression in the tracheal and nasal tissues of rTX-NS-128 immunized chickens was significantly higher than that in killed rTX vaccine immunized chickens 3 days after immunization (P < 0.05) (Figure 4). There was no significant difference in IL-2 and IL-6 expression between rTX-NS-128 and killed rTX vaccine immunized chickens. Both IgA and IgG levels in the tracheal and nasal lavage fluids induced by rTX-NS-128 were significantly higher than that induced by killed rTX vaccine at 7, 14, and 21 dpi (Figure 5).

Immune Responses and Protective Efficacy of rTX-NS1-128 in Chickens

Specific-pathogen-free chickens (4-weeks old) were inoculated intranasally with 10<sup>6</sup> EID<sub>50</sub> of rTX-NS1-128 and were challenged with homologous (TX) and heterologous (F98) H9N2 viruses on day 21 post-inoculation. No virus was shed from chickens vaccinated with rTX-NS1-128, while chickens in the control group shed both viruses after challenge (Table 4). These data suggest that rTX-NS1-128 can provide complete protection in chickens against either H9N2 virus.

DISCUSSION

Oil-emulsion inactivated vaccines are widely used in China to control H9N2. However, antigenic drift has resulted in several new H9N2 AIV genotypes (Li et al., 2005; Jiang et al., 2012) and the protective efficacy of existing H9N2 vaccines has decreased (Sun et al., 2010). Live attenuated vaccines have several advantages, such as induction of humoral, mucosal, and cellular immunity, convenient administration, and cross-protective efficacy (Joseph et al., 2008). Cold-adapted vaccine strains such as LAV (Maassab and Bryant, 1999) have provided excellent protective efficacy in mice and chickens.
TABLE 2 | Viral shedding and titration in chicken oropharyngeal and cloacal swabs.

| Virus | 3 dpi | 5 dpi | 7 dpi | HI |
|-------|-------|-------|-------|-----|
|       | O<sup>a</sup> | C<sup>b</sup> | O | C | O | C | (log<sub>2</sub>)<sup>e</sup> |
| rTX   | 10<sup>10</sup>/10 | 10/10 | 10/10 | 8/10 | 2/10 | 0/10 | 10 |
|       | (6.05 ± 0.55)<sup>c</sup> | | | | | | |
| rTX-Ns1-73 | 9/10 | 0/10 | 8/10 | 0/10 | | | 10 |
|       | (3.55 ± 0.26) | | | | | | |
| rTX-Ns1-100 | 9/10 | 0/10 | 7/10 | 0/10 | | | 10 |
|       | (2.94 ± 0.50) | | | | | | |
| rTX-Ns1-128 | 8/10 | 0/10 | 5/10 | 0/10 | | | 9 |
|       | (1.94 ± 0.27) | | | | | | |

<sup>a</sup>Oropharyngeal swab.

<sup>b</sup>Cloacal swab.

<sup>c</sup>Hi titer of chickens at 21 days post-inoculation.

<sup>d</sup># of positive chickens/total chickens used.

<sup>e</sup>Virus titers: log<sub>10</sub>EID<sub>50</sub>/0.1 ml ± SD.

TABLE 3 | Transmission and dose-response study of wild-type H9N2 (rTX) and NS1-truncated H9N2 (rTX-NS1-128) viruses in chickens.

| Virus/Dose (EID<sub>50</sub>) | Transmission method | 3 dpi | 5 dpi | Seroconversion<sup>c</sup> |
|-----------------------------|---------------------|-------|-------|--------------------------|
|                             |                     | O<sup>a</sup> | C<sup>b</sup> | O | C |      |      |
| rTX – 10<sup>7</sup>        | Inoculation         | 5/5<sup>d</sup> | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
|                             | Contact             | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
| rTX – 10<sup>6</sup>        | Inoculation         | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
|                             | Contact             | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
| rTX – 10<sup>5</sup>        | Inoculation         | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
|                             | Contact             | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
| rTX – 10<sup>4</sup>        | Inoculation         | 3/5 | 3/5 | 3/5 | 2/5 | 2/5 | 1/5 |
|                             | Contact             | 2/5 | 2/5 | 2/5 | 2/5 | 2/5 | 2/5 |
| rTX – 10<sup>3</sup>        | Inoculation         | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| rTX-Ns1-128 – 10<sup>7</sup> | Inoculation         | 5/5<sup>d</sup> | 5/5 | 5/5 | 5/5 | 5/5 | 5/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| rTX-Ns1-128 – 10<sup>6</sup> | Inoculation         | 4/5 | 0/5 | 3/5 | 0/5 | 0/5 | 0/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| rTX-Ns1-128 – 10<sup>5</sup> | Inoculation         | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| rTX-Ns1-128 – 10<sup>4</sup> | Inoculation         | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
| rTX-Ns1-128 – 10<sup>3</sup> | Inoculation         | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |
|                             | Contact             | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 | 0/5 |

<sup>a</sup>Oropharyngeal swab.

<sup>b</sup>Cloacal swab.

<sup>c</sup>Hi titer of chickens 21 days post-inoculation or post-exposure. Hi < 4log<sub>2</sub> was considered negative.

<sup>d</sup># of positive chickens/total chickens used.

(Suguitan et al., 2006). Altering the NS1 gene using reverse genetics is an alternative approach.

The influenza A virus NS1 protein is a multifunctional protein that plays important roles in virus replication and antagonizing host antiviral responses, especially by blocking type I interferon (IFN) responses (Hale et al., 2008). The NS1 protein is 230 amino acids long and contains two distinct functional domains. The N-terminal RNA-binding domain (residues 1-73) prevents the synthesis of IFN-α/β by inhibiting dsRNA-dependent protein kinase R activation. The effector domain (residues 74–230) possesses several different functional epitopes that interact with many different host proteins (Hatada and Fukuda, 1992), including eukaryotic translation initiation factor 4GI (EIF4G) (Aragón et al., 2000), protein kinase R (Li et al., 2006), and cleavage and polyadenylation specific factor (F) (Nemeroff et al., 1998). NS1 is a potent IFN antagonist and mutations/deletions in NS1 result in stronger host stronger IFN responses (Talon et al., 2000; Hale et al., 2008).
Several experimental LAIVs for birds, pigs, and horses have been constructed with NS1 protein truncations (Quinlivan et al., 2005; Vincent et al., 2007; Wang et al., 2008; Hyesun et al., 2016; Shi et al., 2016). Here we generated three NS1 mutant viruses (rTX-NS1-73, rTX-NS1-100, and rTX-NS1-128) by creating C-terminal NS1 truncations. These mutant viruses all replicated in 10-day-old embryonated chicken eggs and MDCK cells but were attenuated relative to the wild-type virus. The degree of attenuation increased as a function of increased NS1 truncation, similar to findings from other studies (Quinlivan et al., 2005).

The nasal mucosa is an effective site for induction of mucosal immunity because of the low threshold for initiation of an immune response. Mucosal immunization also improves local (s-IgA and IgG) antibody responses (Macpherson et al., 2008). We evaluated the potential of the most attenuated mutant virus, rTX-NS1-128, as a live vaccine. The rTX-NS1-128 live vaccine induced enhanced mucosal immunity responses, suggesting that it could more effectively resist infection of H9N2 influenza virus. Cellular immunity in the mucosal site also plays an important role in early immune responses to prevent pathogens from entering the epithelium. Live vaccines can promote the
TABLE 4 | Protective efficacy induced by rTX-NS1-128 in SPF chickens.

| Group       | Challenge virus | 3 dpi | 5 dpi | 7 dpi |
|-------------|----------------|-------|-------|-------|
|             |                 | O\(^a\) | O\(^b\) | C      | O     | C     |
| rTX-NS1-128 | F98 (H9N2)      | 0/10  | 0/10  | 0/10  | 0/10  | 0/10  |
| rTX-NS1-128 | TX (H9N2)       | 0/10  | 0/10  | 0/10  | 0/10  | 0/10  |
| Control     | F98 (H9N2)      | 10/10 | 9/10  | 10/10 | 9/10  | 2/10  |
| Control     | TX (H9N2)       | 10/10 | 10/10 | 3/10  | 2/10  |

\(^a\)Oropharyngeal swab.  
\(^b\)Cloacal swab.

We conclude that rTX-NS1-128 could be used to control and prevent H9N2 AIV infections. Although NS1-truncation-based LAVs appear to be stable (Egorov et al., 1998; Donelan et al., 2003), there is a concern that live-attenuated vaccines may revert to virulence. In the future we will pursue the construction of dual fail-safe LAVs that possess both a truncated NS1 protein as well as temperature-sensitivity.

AUTHOR CONTRIBUTIONS

DP, SC, and YZ participated in the design of the study. SC, YZ, DY, YY, and SS performed the experiment. SC, YZ, and TQ analyzed the data and drafted the manuscript. DP and XL planned the experiments and helped write the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

This study was supported by the National key R&D Project (2017YFD0500701; 2016YFD0500202; 2016YFD0501602; 2016YFD0500803), the Agricultural Science & Technology Independent Innovation Fund of Jiangsu Province [CX(15)1065], the Sanxin Engineering Project for Jiangsu Agriculture (SXGC[2014]311), the Special Fund for Agro-scientific Research in the Public Interest (20100312), the National High-Tech Research and Development Program of China, the Natural Science Foundation of Yangzhou City (YZ2014028), the top talent support project of Yangzhou University, and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: http://journal.frontiersin.org/article/10.3389/fmicb.2017.01086/full#supplementary-material

FIGURE S1 | Sequence analysis of NS1 gene. Total RNAs were extracted and NS1 genes were amplified for sequence analysis.
REFERENCES

Allan, W. H., Lancaster, J. E., and Toth, B. (1978). *Newcastle Disease Vaccines, their Production and Use*. Rome: Food and Agriculture Organization.

Aragón, T., Luna, S. D. L., Novoa, I. Carrasco, L., Ortiz, J., and Nieto, A. (2000). Eukaryotic translation initiation factor 4GI is a cellular target for NS1 protein, a translational activator of influenza virus. *Mol. Cell. Biol.* 20, 6259–6268. doi: 10.1128/mcb.20.24.6259-6268.2000

Butt, K. M., Smith, G. J., Chen, H., Zhang, L. J., Xu, K. M., et al. (2005). Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. *J. Clin. Microbiol.* 43, 5760–5767. doi: 10.1128/JCM.43.11.5760-5767.2005

Chen, H., Yuan, G., Gao, K., Zhang, J., Wang, D., Xiong, Y., et al. (2014). Clinical and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. *Lancet* 383, 714–721. doi: 10.1016/S0140-6736(14)60111-2

Donelan, N. B., Basler, C. F., and Garcia-Sastre, A. (2003). A recombinant influenza A virus expressing a RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. *J. Virol.* 77, 13257–13266. doi: 10.1128/jvi.77.24.13257-13266.2003

Egorov, A., Brandt, S., Sereining, S., Romanova, J., Ferko, B., Katinger, D., et al. (1998). Transfected influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. *J. Virol.* 72, 6437–6441.

Fleming, D. M., Cровари, P., Wahn, U., Klemola, T., Schlesinger, Y., Langussis, A., et al. (2006). Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. *Pediatr. Infect. Dis. J.* 25, 860–869. doi: 10.1097/01.inf.0000237797.14283.cf

Hale, B. G., Randall, R. E., Ortin, J., and Jackson, D. (2008). The multifunctional NS1 protein of influenza A viruses. *J. Virol.* 82, 2359–2376. doi: 10.1128/vir.2008.00460-6

Hatada, E., and Fukuda, R. (1992). Binding of influenza A virus NS1 protein to dsRNA in vitro. *J. Gen. Virol.* 73(Pt 12), 3325–3329. doi: 10.1099/0022-1317-73-12-3325

Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., and Webster, R. G. (2000). A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. U.S.A.* 97, 6108–6113. doi: 10.1073/pnas.100133697

Hyesun, J., Nguni, J. M., and Chang-Won, L. (2016). Association between interferon response and protective efficacy of NS1-truncated mutants as influenza vaccine candidates in chickens. *PLoS ONE* 11(5):e0156603. doi: 10.1371/journal.pone.0156603

Jiang, W., Liu, S., Hou, G., Li, J., Zhuang, Q., Wang, S., et al. (2012). Chinese and epidemiological characteristics of a fatal case of avian influenza A H10N8 virus infection: a descriptive study. *Lancet* 383, 714–721. doi: 10.1016/S0140-6736(99)03311-5

Quinlivan, M., Zamarlin, D., García-Sastre, A., Cullmann, A., Chambers, T., and Palese, P. (2005). Attenuation of equine influenza viruses through truncations of the NS1 protein. *J. Virol.* 79, 8431–8439. doi: 10.1128/JVI.79.13.8431-8439.2005

Rauw, F., Gardin, Y., Palva, V., Anzari, S., Gonzalez, M., Lemaire, S., et al. (2010). The positive adjuvant effect of chitosan on antigen-specific, cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. *Vet. Immunol. Immunopathol.* 134, 249–258. doi: 10.1016/j.vetimm.2009.10.028

Reed, L. J., and Muench, H. (1938). A simple method of estimating fifty per cent endpoints. *Am. J. Hyg.* 27, 493–497. doi: 10.1093/oxfordjournals.aaj.a118408

Shi, S., Chen, S., Han, W., Wu, B., Zhang, X., Tang, Y., et al. (2016). Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines. *Vaccine* 34, 350–357. doi: 10.1016/j.vaccine.2015.11.045

Shin, J. H., Mo, J. S., Kim, J. N., Mo, I. P., and Ha, B. D. (2016). Assessment of the safety and efficacy of low pathogenic avian influenza (H9N2) virus in inactivated oil emulsion vaccine in laying hens. *J. Vet. Sci.* 17, 27–34. doi: 10.4142/jvs.2016.17.1.27

Suguitan, A. L. Jr., McAuliffe, J., Mills, K. L., Jin, H., Duke, G., Lu, B., et al. (2006). Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. *PLoS Med.* 3:e360. doi: 10.1371/journal.pmed.0030360

Sun, Y., Pu, J., Fan, L., Sun, H., Wang, J., Zhang, Y., et al. (2012). Evaluation of the protective efficacy of a commercial vaccine against different antigenic groups of H9N2 influenza viruses in chickens. *Vet. Microbiol.* 156, 193–199. doi: 10.1016/j.vetmic.2011.10.003

Sun, Y., Pu, J., Jiang, Z., Tiao, Y., Xu, Q., et al. (2010). Genetic evolution and antigenic drift of H9N2 influenza viruses in China from 1994 to 2008. *Vet. Microbiol.* 146, 215–225. doi: 10.1016/j.vetmic.2010.05.010

Talon, J., Salvatore, M., O’Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., et al. (2000). Influenza A and B viruses expressing altered NS1 proteins: a vaccine approach. *Proc. Natl. Acad. Sci. U.S.A.* 97, 4309–4314. doi: 10.1073/pnas.07052597

Vincent, A. L., Ma, W., Lager, K. M., Janke, B. H., Webby, R. J., Garcia-Sastre, A., et al. (2007). Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. *Vaccine* 25, 7999–8009. doi: 10.1016/j.vaccine.2007.09.019

Wang, L., Suarez, D. L., Pantin-Jackwood, M., Mibayashi, M., Garcia-Sastre, A., Saif, Y. M., et al. (2008). Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. *Vaccine* 26, 3580–3586. doi: 10.1016/j.vaccine.2008.05.001

Wei, Y., Xu, G., Zhang, G., Wen, C., Anwar, F., Wang, S., et al. (2016). Antigenic evolution of H9N2 chicken influenza viruses isolated in China during 2009–2013 and selection of a candidate vaccine strain with broad cross-reactivity. *Vet. Microbiol.* 182, 1–7. doi: 10.1016/j.vetmic.2015.10.031

Wu, A., Su, C., Wang, D., Peng, Y., Liu, M., Hua, S., et al. (2013). Sequential reassortments underlie diverse influenza H7N9 genotypes in China. *Cell Host Microbe* 14, 446–452. doi: 10.1016/j.chom.2013.09.001

Zhou, B., Li, Y., Belser, J. A., Pearce, M. B., Schmolke, M., Subba, A. X., et al. (2010). NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. *Vaccine* 28, 8015–8025. doi: 10.1016/j.vaccine.2010.08.106

Zhu, Y., Yang, D., Ren, Q., Yang, Y., Liu, X., Xu, X., et al. (2015a). Identification and characterization of a novel antigenic epitope in the hemagglutinin of the escape mutants of H9N2 avian influenza viruses. *Vet. Microbiol.* 178, 144–149. doi: 10.1016/j.vetmic.2015.04.012
Zhu, Y., Yang, Y., Liu, W., Liu, X., Yang, D., Sun, Z., et al. (2015b). Comparison of biological characteristics of H9N2 avian influenza viruses isolated from different hosts. Arch. Virol. 160, 917–927. doi: 10.1007/s00705-015-2337-y

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.